ARCHIVES

ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial.

This article is from The Cancer Letter archive.

Vol. 32 No. 31 | September 8, 2006

Download PDF Visit The Full Archive

Related Articles

In Legal Brawl, UPenn and Abramson Institute Allege Former Director Craig Thompson “Absconded” With Inventions

March 9, 2012

Sullivan Accuses Tobacco Industry With “Lies, Blue smoke And Mirrors”

June 15, 1990

CPRIT Awards $107.2 Million Round of Grants

September 5, 2014

Society Support Program for Training Cytotechnologists

November 29, 1991

Chemo Combinations Tested In Phase III For Lung Cancer

August 31, 2001

Pacific Yew Act Would Result In Duplications, Delays In Taxol Production, Witnesses Say

March 13, 1992